Research into psilocybin for chemotherapy-induced peripheral neuropathy is opening a new direction in supportive cancer care. Rather than treating nerve pain after it develops, scientists are investigating whether vulnerable sensory nerves can be protected before chemotherapy causes lasting damage.
A Persistent Cost Of Cancer Treatment
Chemotherapy-induced peripheral neuropathy can produce numbness, burning pain, cold sensitivity, and impaired touch, particularly in the hands and feet. Platinum-based drugs and taxanes are among the treatments most frequently associated with this complication.
Neuropathy may also force clinicians to reduce chemotherapy doses or discontinue an otherwise effective treatment. Current options remain limited, especially for prevention. Clinical guidance supports duloxetine for some patients with established painful neuropathy, but no medication has demonstrated sufficient evidence to become a standard preventive therapy.
Testing Psilocybin Before Chemotherapy
A study published in Science examined whether administering psilocybin before chemotherapy could prevent neuropathy rather than attempting to reverse it later.
Researchers tested the approach across preclinical models involving platinum-based and taxane-based chemotherapy. The experiments included repeated treatment cycles, tumor-bearing mice, human stem cell-derived sensory neurons, and freshly isolated human peripheral nerve tissue.
This combination allowed the investigators to evaluate behavioral symptoms, nerve structure, electrical activity, mitochondrial movement, and potential interference with chemotherapy’s anticancer effects.
Psilocybin For Chemotherapy-Induced Peripheral Neuropathy Shows Durable Protection
As few as two psilocybin doses administered before chemotherapy prevented mechanical hypersensitivity in an initial mouse model. When dosing was aligned with repeated chemotherapy cycles, protection continued across six cycles and more than eight months of follow-up.
Psilocybin also preserved tactile sensitivity and intraepidermal nerve fibers, the small sensory endings in the skin that are frequently damaged during chemotherapy.
Importantly, the intervention did not measurably weaken chemotherapy’s antitumor activity in the models tested. That finding addresses an essential question for any proposed neuroprotective treatment, although confirmation in human cancer care remains necessary.
Mitochondrial Movement Emerges As The Central Mechanism
Sensory axons can extend across long distances and require a continuous supply of energy. Mitochondria must therefore travel through these nerve fibers and reach distal endings, where metabolic demands are high.
Chemotherapy disrupted this transport system, leaving mitochondria improperly distributed and vulnerable nerve endings with reduced energy support. Psilocybin preserved mitochondrial trafficking through signaling involving the 5-HT2A receptor and the TrkB-Akt-PAK5-MAP2-KIF5B pathway.
The treatment also helped remobilize mitochondria anchored by syntaphilin, a protein that normally holds them in place. Restoring movement allowed mitochondria to redistribute along the axon and support areas at risk of degeneration.
Protection Extended Beyond Peripheral Nerves
The effects were not limited to sensory nerve endings. Psilocybin normalized chemotherapy-related changes in synaptic activity within the medial prefrontal cortex and restored altered alpha and beta electroencephalography power.
These findings suggest that the treatment may stabilize both peripheral nerve function and central neural activity. The two effects may reflect partly independent processes rather than a single pathway responsible for every measured outcome.
A Non-Hallucinogenic Compound Adds An Important Clue
Researchers also tested tabernanthalog, or TBG, a non-hallucinogenic 5-HT2A receptor agonist. TBG produced similar protection against mechanical hypersensitivity in mice.
This result suggests that psychedelic experiences may not be required for at least part of the observed neuroprotection. It also creates a broader research question: whether compounds targeting the same receptor system could protect nerves while avoiding perceptual effects.
Human Tissue Strengthens The Translational Case
Experiments using human sensory neurons and freshly isolated peripheral nerves showed that psilocybin preserved mitochondrial movement after chemotherapy exposure. These models cannot predict clinical effectiveness, but they indicate that the biological pathway is present in human nerve tissue.
The study is therefore more than a behavioral experiment in mice. It connects sensory outcomes with a defined cellular mechanism and tests whether that mechanism appears across species and chemotherapy classes.
Clinical Evidence Must Come Next
Psilocybin has not been proven to prevent chemotherapy-induced neuropathy in patients and is not approved for this purpose. Human trials must establish appropriate dosing, timing, safety, drug interactions, and whether nerve protection can be achieved without compromising cancer treatment.
For now, the study identifies mitochondrial trafficking as a promising preventive target. Its most consequential idea may be that preserving the nerve’s energy distribution system before injury occurs could be more effective than trying to repair damage afterward.
Citations
Heles M, Pasvolsky L, Sathishkumar H, et al. “Psilocybin Prevents Chemotherapy-Induced Peripheral Neuropathy Through Mitochondrial Trafficking Preservation.” Science. 2026;393(6815):eaec6116.
Loprinzi CL, Lacchetti C, Bleeker J, et al. “Prevention And Management Of Chemotherapy-Induced Peripheral Neuropathy In Survivors Of Adult Cancers.” Journal of Clinical Oncology. 2020;38(28):3325-3348.
Explore more at https://www.interventionalpsychiatry.org/
